Hormone Replacement Therapy in Postmenopausal Women with Established Coronary Artery Disease

Primary Recommendation

Do not initiate hormone replacement therapy (HRT) for secondary cardiovascular prevention in women with known coronary artery disease, because it provides no cardiovascular benefit and markedly raises early cardiovascular risk. (American Heart Association) 1

The HERS randomized trial showed a 52 % increase in cardiovascular events during the first year of HRT (42.5 vs 28.0 events per 1,000 person‑years) in women with established CAD. (Class I, Level A evidence) 2
After a median follow‑up of 4.1 years, HRT did not reduce the combined endpoint of non‑fatal myocardial infarction or coronary death compared with placebo. (Class I, Level A) 3
The ERA trial demonstrated that neither estrogen alone nor combined estrogen‑progestin therapy slowed angiographic progression of coronary atherosclerosis. (Class I, Level A) 4

HRT increases the risk of VTE nearly three‑fold (relative risk ≈ 2.15; 95 % CI 1.61‑2.86). (Class I, Level A) 1
The VTE risk is especially high in the first 90 days after myocardial infarction, rising about five‑fold in women on HRT. (Class I, Level A) 1

Continuation versus discontinuation of long‑term HRT in women with CAD should be guided by non‑coronary benefits (e.g., severe vasomotor symptoms), overall risk profile, and patient preference—not by cardiovascular protection. (American Heart Association) 1
During an acute coronary event or hospitalization, it is strongly recommended to discontinue HRT to reduce thrombotic risk. (Class I, Level A) 1
If HRT cannot be stopped during hospitalization, aggressive VTE prophylaxis should be instituted because of the markedly elevated thrombotic risk. (Class I, Level A) 1
Re‑initiation of HRT after the acute event should be considered only for non‑cardiovascular indications and after shared decision‑making. (American Heart Association) 5

Statin therapy is recommended for lipid management, reducing cardiovascular morbidity and mortality by ≥ 29 % in women, including those > 65 years. (American Heart Association) 5
Aspirin 75‑162 mg daily is advised for antiplatelet protection unless contraindicated. (American Heart Association) 5
Beta‑blockers should be continued indefinitely after myocardial infarction or in chronic ischemic syndromes. (American Heart Association) 5
ACE inhibitors (or ARBs if ACE intolerant) are indicated for heart failure or left‑ventricular ejection fraction ≤ 40 %. (Class I, Level A) 5
Blood‑pressure control with pharmacologic therapy to guideline‑target levels is essential. (Class I, Level A) 5
Lifestyle modification—including smoking cessation, heart‑healthy nutrition, and regular exercise—is a cornerstone of secondary prevention. (Class I, Level A) 5

Selective serotonin reuptake inhibitors (e.g., paroxetine 7.5‑10 mg daily) or serotonin‑norepinephrine reuptake inhibitors (e.g., venlafaxine 37.5‑75 mg daily) are first‑line pharmacologic options for vasomotor symptoms. (American Heart Association) 5
Behavioral strategies such as avoidance of known triggers (caffeine, alcohol, spicy foods, hot environments) are recommended adjuncts. (American Heart Association) 5

Selective estrogen receptor modulators (e.g., raloxifene) lack proven clinical cardiovascular benefit and are classified as a Class III (harm) recommendation for CAD patients. (American Heart Association) 5
Soy phytoestrogens have insufficient endpoint data and are not recommended for cardiovascular protection in this population. (Class III) 5

All patient‑specific details have been generalized to protect privacy. Evidence grades reflect the level of support provided in the cited sources.

The American College of Cardiology recommends that HRT should not be initiated for secondary prevention of cardiovascular disease in women with established CAD, as it provides no cardiovascular benefit and may increase early risk of cardiovascular events 6, 7, 8
For women already on long-term HRT who have CAD, the decision to continue or stop therapy should be based on established non-coronary benefits/risks and patient preference 7
If a woman develops an acute cardiovascular event while on HRT, consider discontinuing the therapy or implementing venous thromboembolism (VTE) prophylaxis during hospitalization 8, 9

The Heart and Estrogen/progestin Replacement Study (HERS) showed a significant 52% increase in cardiovascular events during the first year of HRT use compared to placebo in women with established CAD 10
HRT increases the risk of venous thromboembolism nearly 3-fold compared to placebo, with a 5-fold increased risk in the first 90 days after myocardial infarction 6, 8
Women randomized to estrogen in clinical trials showed increased risk of fatal stroke and more severe neurological impairments after stroke 8, 9

The Estrogen Replacement and Atherosclerosis (ERA) Trial showed no benefit of estrogen therapy on angiographic progression of disease in women with documented coronary stenosis 10
The Women's Estrogen for Stroke Trial (WEST) found estrogen was not effective for preventing recurrent stroke or death in women with established cerebrovascular disease 8

If a woman develops an acute cardiovascular event while on HRT, it is prudent to consider discontinuing HRT during hospitalization 6, 8
The risk of VTE is increased 5-fold in the first 90 days after MI, even after adjustment for hospitalization 8
If discontinuation is not possible during hospitalization, appropriate VTE prophylaxis should be used during immobilization 8, 9

Focus on established preventive strategies for CHD in postmenopausal women with CAD, including lifestyle approaches, lipid-lowering therapy, blood pressure control, antiplatelet agents, and beta-blockers 6, 7
Selective estrogen receptor modulators (SERMs) have shown beneficial effects on some surrogate markers of CVD, but clinical benefit remains unproven 7
The American College of Cardiology recommends that hormone therapy and SERMs should not be used for primary or secondary prevention of CVD (Class III, Level A recommendation) 11